Sugi Predict

Sugi Predict / Targets / GUCY1A2

GUCY1A2

Guanylate cyclase soluble subunit alpha-2 (GC · P33402 · GUCY1A2 on Sugi Atlas →

14,016 patent compounds predicted against GUCY1A2, 7,828 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL3437351 SCHEMBL3437351 1.00 20/20
SCHEMBL3439299 SCHEMBL3439299 1.00 20/20
SCHEMBL3436905 SCHEMBL3436905 0.87 20/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL253278) 0.85 20/20
SCHEMBL3436772 SCHEMBL3436772 0.84 20/20
SCHEMBL3437332 SCHEMBL3437332 0.83 20/20
SCHEMBL3436902 SCHEMBL3436902 0.82 20/20
SCHEMBL3436748 SCHEMBL3436748 0.81 20/20
SCHEMBL3436958 SCHEMBL3436958 0.81 20/20
SCHEMBL3437524 SCHEMBL3437524 0.81 20/20
SCHEMBL3437258 SCHEMBL3437258 0.80 20/20
SCHEMBL3437391 SCHEMBL3437391 0.80 20/20
SCHEMBL250991 SCHEMBL250991 0.79 20/20
SCHEMBL3437270 SCHEMBL3437270 0.79 20/20
SCHEMBL3436741 SCHEMBL3436741 0.78 20/20
SCHEMBL3436918 SCHEMBL3436918 0.78 20/20
SCHEMBL3439338 SCHEMBL3439338 0.78 20/20
SCHEMBL252290 SCHEMBL252290 0.78 20/20
SCHEMBL3439239 SCHEMBL3439239 0.77 20/20
SCHEMBL3436743 SCHEMBL3436743 0.77 20/20

Clinical trials — most relevant to GUCY1A2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Switching of Sildenafil to Riociguat in CTEPH Patients PHASE4RECRUITING
The Effect of Vericiguat on Peripheral Vascular Function, Patient Health Status and Inflammation PHASE4COMPLETED
Vericiguat and Reverse Remodeling Indices in Heart Failure PHASE4RECRUITING
Bosentan in Treatment of Pulmonary Arterial Hypertension PHASE4COMPLETED
Impact of Vericiguat on Hemodynamics of Heart Failure PHASE4ACTIVE_NOT_RECRUITING
Methylene Blue and Microcirculation in Septic Shock PHASE3UNKNOWN
Use of Sildenafil Citrate in Management of Mild Pre-eclampsia PHASE2/PHASE3UNKNOWN
Chronic Sildenafil Treatment in Heart Failure PHASE3COMPLETED
The Efficacy and Safety of Vardenafil in the Treatment of Pulmonary Arterial Hypertension PHASE3COMPLETED
Safety Study of Sildenafil in Treatment of Cerebral Aneurysm Vasospasm PHASE2WITHDRAWN
Dietary Nitrate and Nitrite to Increase Nitric Oxide in Patients With Coronary Artery Disease PHASE2COMPLETED
Networked Drug REpurposing for Mechanism-based neuroPrOtection in Acute Ischaemic STROKE PHASE2UNKNOWN
STRETCH Study: Effect of Distensibility on Endothelial-Dependent Vasoreactivity in Patients With ISH PHASE2COMPLETED
Tadalafil for Pulmonary Hypertension Due to Chronic Lung Disease PHASE2COMPLETED
The STRETCH Study: Distensibility on Endothelial-Dependent Vasoreactivity in Subjects With Systolic Hypertension PHASE2COMPLETED
Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old PHASE2ACTIVE_NOT_RECRUITING
Effects of Nitrite on Blood Vessel Dilation in Normal Volunteers PHASE2COMPLETED
Pentoxifylline as an Adjunctive in Treatment of Negative Symptoms in Chronic Schizophrenia PHASE1/PHASE2COMPLETED
A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16) PHASE2COMPLETED
Study to Evaluate Safety and Efficacy of Mirivadelgat in PH-ILD PHASE2RECRUITING
PDE5 Inhibition for Obesity-Related Cardiometabolic Dysfunction PHASE2COMPLETED
Vascular Effects of Endothelium-Derived Versus Hemoglobin-Transported Nitric Oxide in Healthy Subjects PHASE1COMPLETED
Trial of IW-1701 (A Stimulator of Soluble Guanylate Cyclase (sGC)) in Healthy Volunteers PHASE1COMPLETED
: Vascular Function in Health and Disease PHASE1RECRUITING
Vitamin D Versus Sildenafil Citrate in Fetal Growth Restriction PHASE1COMPLETED
Uterine Artery Doppler Changes After Vaginal Administration of Isosorbide Mononitrate In Patients With URPL EARLY_PHASE1UNKNOWN
GSNOR Phenotyping/GSNO Challenge in Severe Asthma EARLY_PHASE1COMPLETED
The Effect of Polymorphism of the GUCY1A3 rs7692387 Gene on Cardiovascular Events After Coronary Artery Bypass Grafting. nanUNKNOWN
Intravenous Terbutaline in Severe Status Asthmaticus nanUNKNOWN
Forced Oscillometry in Infants With Bronchopulmonary Dysplasia nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a GUCY1A2 binder may also engage these)

ProteinNameSimilarity
P19687 — 1.000 P19687 →
Q9WVI4 — 0.999 Q9WVI4 →
GUCY1A1 Guanylate cyclase soluble subunit alpha-1 (GC 0.996 landscape →
Q9ERL9 — 0.995 Q9ERL9 →
Q4ZHS0 — 0.994 Q4ZHS0 →
P19686 — 0.993 P19686 →
Q6DNF7 — 0.991 Q6DNF7 →
Q07093 — 0.989 Q07093 →
P70600 — 0.987 P70600 →
P92006 — 0.986 P92006 →
O15068 — 0.986 O15068 →
Q5XHF8 — 0.985 Q5XHF8 →
E9PUQ8 — 0.985 E9PUQ8 →
Q66K14 — 0.985 Q66K14 →
Q63406 — 0.984 Q63406 →
Q64096 — 0.984 Q64096 →
Q60629 — 0.984 Q60629 →
P97874 — 0.984 P97874 →
P22717 — 0.984 P22717 →
O14830 — 0.984 O14830 →
B0R0W9 — 0.984 B0R0W9 →
Q16760 — 0.983 Q16760 →
Q008S8 — 0.983 Q008S8 →
O35385 — 0.983 O35385 →
F6QZ15 — 0.983 F6QZ15 →
Q9Y4B4 — 0.982 Q9Y4B4 →
Q5SVR0 — 0.982 Q5SVR0 →
Q62688 — 0.982 Q62688 →
B3M1E1 — 0.982 B3M1E1 →
F8VPU2 — 0.982 F8VPU2 →